Primary cutaneous cryptococcosis during infliximab therapy

Dermatol Ther. 2017 Jan;30(1). doi: 10.1111/dth.12405. Epub 2016 Sep 16.

Authors

Anca Chiriac¹, Mihai Mares², Doina Mihaila³, Caius Solovan⁴, Cosmin Moldovan⁵, Simona Stolnicu⁶, Ferry Hagen⁷

Affiliations

¹ Department of Dermatology, Apollonia University, Iasi, Romania.
² Laboratory of Antimicrobial Chemotherapy, "Ion Ionescu de la Brad" University, Iasi, Romania.
³ Department of Pathology, Saint Mary Emergency Hospital for Children, Iasi, Romania.
⁴ Department of Dermatology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
⁵ Department of Histology, University of Medicine and Pharmacy of Tirgu Mures, Romania.
⁶ Department of Pathology, University of Medicine and Pharmacy of Tirgu Mures, Romania.
⁷ Department of Medical Microbiology & Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.

PMID: 27637071
DOI: 10.1111/dth.12405

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Oral
Aged
Antifungal Agents / administration & dosage
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / diagnosis
Arthritis, Rheumatoid / drug therapy*
Biopsy
Cryptococcosis / chemically induced*
Cryptococcosis / drug therapy
Cryptococcosis / immunology
Cryptococcosis / microbiology
Cryptococcus neoformans / immunology
Cryptococcus neoformans / isolation & purification*
Dermatomycoses / chemically induced*
Dermatomycoses / drug therapy
Dermatomycoses / immunology
Dermatomycoses / microbiology
Drug Administration Schedule
Female
Fluconazole / administration & dosage
Humans
Immunocompromised Host
Infliximab / adverse effects*
Opportunistic Infections / chemically induced*
Opportunistic Infections / drug therapy
Opportunistic Infections / immunology
Opportunistic Infections / microbiology
Treatment Outcome

Substances

Antifungal Agents
Antirheumatic Agents
Fluconazole
Infliximab